These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 28066879

  • 1. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
    Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N.
    Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1192-1196. PubMed ID: 27741335
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.
    Br J Dermatol; 2019 Nov 01; 181(5):967-975. PubMed ID: 30916379
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series.
    Abdalla T, Mansour M, Bouazzi D, Lowes MA, Jemec GBE, Alavi A.
    Am J Clin Dermatol; 2021 Mar 01; 22(2):275-283. PubMed ID: 33242185
    [Abstract] [Full Text] [Related]

  • 5. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE.
    J Am Acad Dermatol; 2019 Jan 01; 80(1):60-69.e2. PubMed ID: 29860040
    [Abstract] [Full Text] [Related]

  • 6. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):490-497. PubMed ID: 27545848
    [Abstract] [Full Text] [Related]

  • 7. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A, Takahashi H, Ozawa K, Imafuku S, Nakama T, Takahashi K, Matsuyama T, Okubo Y, Kitamura S, Matsuda N, Zhao Y, Yokoyama M, Hayashi N, Terui T.
    J Dermatol; 2019 Sep 01; 46(9):745-751. PubMed ID: 31282051
    [Abstract] [Full Text] [Related]

  • 8. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Jiménez-Gallo D, de la Varga-Martínez R, Ossorio-García L, Collantes-Rodríguez C, Rodríguez C, Linares-Barrios M.
    Cytokine; 2018 Mar 01; 103():20-24. PubMed ID: 29289722
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.
    Ann Intern Med; 2012 Dec 18; 157(12):846-55. PubMed ID: 23247938
    [Abstract] [Full Text] [Related]

  • 10. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB.
    N Engl J Med; 2016 Aug 04; 375(5):422-34. PubMed ID: 27518661
    [Abstract] [Full Text] [Related]

  • 11. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA.
    Am J Clin Dermatol; 2018 Jun 04; 19(3):437-447. PubMed ID: 29380251
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ.
    Expert Opin Drug Saf; 2020 Apr 04; 19(4):381-393. PubMed ID: 32098513
    [Abstract] [Full Text] [Related]

  • 13. Emerging drugs for the treatment of hidradenitis suppurativa.
    Folkes AS, Hawatmeh FZ, Wong A, Kerdel FA.
    Expert Opin Emerg Drugs; 2020 Sep 04; 25(3):201-211. PubMed ID: 32667213
    [Abstract] [Full Text] [Related]

  • 14. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.
    Arch Dermatol; 2009 May 04; 145(5):580-4. PubMed ID: 19451504
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
    Bechara FG, Podda M, Prens EP, Horváth B, Giamarellos-Bourboulis EJ, Alavi A, Szepietowski JC, Kirby J, Geng Z, Jean C, Jemec GBE, Zouboulis CC.
    JAMA Surg; 2021 Nov 01; 156(11):1001-1009. PubMed ID: 34406349
    [Abstract] [Full Text] [Related]

  • 16. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB.
    J Eur Acad Dermatol Venereol; 2016 Jun 01; 30(6):989-94. PubMed ID: 26201313
    [Abstract] [Full Text] [Related]

  • 17. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
    Bi Y, Liu J, Wang J, Epps RE, Kettl D, Marcus K, Seo S, Zhu H, Wang Y.
    AAPS J; 2019 Jul 19; 21(5):91. PubMed ID: 31325056
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, Rosh JR, Ruemmele FM, Awni WM.
    Inflamm Bowel Dis; 2015 Apr 19; 21(4):783-92. PubMed ID: 25723614
    [Abstract] [Full Text] [Related]

  • 19. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
    Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M.
    Dermatol Online J; 2016 Mar 16; 22(3):. PubMed ID: 27136622
    [Abstract] [Full Text] [Related]

  • 20. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC, Hansen H, Caposiena Caro RD, Damiani G, Delorme I, Pascual JC, Reguiai Z, Trigoni A, Vilarrasa E, Alfageme Roldán F.
    Dermatology; 2020 Mar 16; 236(1):25-30. PubMed ID: 31630144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.